This study will use a 22 gene pharmacogenomics panel on 30 children with persistent Gastroesophageal Reflux Disease (GERD) who have not responded to therapy.
This study will assess the clinical utility of pharmacogenomics testing in the clinical management of children with refractory GERD, despite adequate therapy and the role of pharmacogenomics in selecting the right acid suppressive therapy based on each patient's symptoms and pharmacogenomics results.
Study Type
OBSERVATIONAL
Enrollment
51
Mayo Clinic
Rochester, Minnesota, United States
Number of subjects who change medication due to pharmacogenomic results
Time frame: 12 weeks
Number of subjects who have a repeat scope
Time frame: 12 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.